Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
KardiganCompany profile Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond. Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond. | $300M | Series A | Biotech | United States | Investors | |
SRTD BiotechCompany profile SRTD Biotech develops RNA therapies designed to activate selectively inside diseased cells. SRTD Biotech develops RNA therapies designed to activate selectively inside diseased cells. | Undisclosed | Seed | Biotech | Germany | Investors | |
| LB Laigo BioCompany profile Laigo Bio develops targeted protein degradation therapies for cancer and autoimmune diseases. Laigo Bio develops targeted protein degradation therapies for cancer and autoimmune diseases. | Undisclosed | TKI-MKB research grantUndisclosed | Biotech | Netherlands | Investors | |
| T Saliva-based diagnostics that measure a person’s circadian rhythm. | €75K | Women TechEU grantUndisclosed | Biotech, Healthtech | Germany | Investors | |
BioGeometryCompany profile BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering. BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering. | Undisclosed | Pre-ASeed | Biotech | China | Investors | |
| RB Revascular Bio Co., Ltd.Company profile Revascular Bio develops cell therapies using vascular endothelial stem cells. Revascular Bio develops cell therapies using vascular endothelial stem cells. | Undisclosed | AMED drug-discovery ecosystem grantUndisclosed | Biotech | Japan | Investors | |
| AT Alchemab TherapeuticsCompany profile Alchemab Therapeutics develops antibody medicines by studying people resilient to disease. Alchemab Therapeutics develops antibody medicines by studying people resilient to disease. | $595K | Parkinson research grantUndisclosed | Biotech | United Kingdom | Investors | |
| DT Delix TherapeuticsCompany profile Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders. Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders. | $825K | Department of Defense research grantUndisclosed | Biotech | United States | Investors | |
| mI molmir Inc.Company profile molmir develops ways to observe molecular dynamics and uses that knowledge to identify new targets for medicines. molmir develops ways to observe molecular dynamics and uses that knowledge to identify new targets for medicines. | Undisclosed | Seed | Biotech | Japan | Investors | |
| E French foodtech company making protein-rich ingredients from spirulina. | €2M | Pre-seed | Biotech, Foodtech | France | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.